Following thepublication of several high-profile studies implicating PPARδ as a potential target for obesity andassociated metabolic disorders, multiple pharmaceutical companies haveinitiated drug discovery efforts to identify specific PPARδ, PPARα/δ, PPARγ/δ, and pan PPAR modulators. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.